About this trial
This prospective randomized open-label study aims to compare the effectiveness of two dual antihypertensive therapy regimens in patients with arterial hypertension and coronary artery disease after elective percutaneous coronary intervention (PCI) with coronary artery stenting.
Patients requiring dual antihypertensive therapy will be randomized to receive either an angiotensin receptor blocker (ARB) combined with a thiazide diuretic or an ARB combined with a dihydropyridine calcium channel blocker.
The study will evaluate blood pressure control, angina symptoms, quality of life, need for treatment intensification, and healthcare utilization during follow-up. Clinical status will be assessed at discharge and during telemedicine follow-up visits at 2 weeks, 4 weeks, and 12 weeks after hospital discharge.
The primary endpoint is the percentage reduction in systolic and diastolic blood pressure. Secondary endpoints include frequency of angina episodes, exercise limitations, patient satisfaction with treatment, and medical consultations during follow-up.
The study is investigator-initiated and plans to enroll at least 207 participants.
Eligibility criteria
Qualifiers
Age 50 to 70 years
Arterial hypertension
Coronary artery disease
Hospitalization for elective percutaneous coronary intervention
Disqualifiers
Refusal or inability to provide informed consent
Acute coronary syndrome
Active malignancy
Pulmonary embolism
Trial design
Treatments tested in this trial
- Losartan + Hydrochlorothiazide
- Amlodipine + Azilsartan